Nektar Therapeutics Company Profile (NASDAQ:NKTR)

About Nektar Therapeutics

Nektar Therapeutics logoNektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company's pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. The Company's drugs include MOVANTIK (naloxegol) tablets, MOVENTIG, AdYnoVATE, NKTR-102 (next-generation topoisomerase I inhibitor), BAY41-6551 (Amikacin inhale, formerly NKTR-061), NKTR-181 (orally-available mu-opioid analgesic molecule), NKTR-102, NKTR-214 and MoVAnTiK fixed-dose combinations (opioid/naloxegol combinations). Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: NKTR
  • CUSIP: 64026810
Key Metrics:
  • Previous Close: $17.83
  • 50 Day Moving Average: $16.273
  • 200 Day Moving Average: $14.443
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -21.12
  • P/E Growth: 2.130
  • Market Cap: $2.48B
  • Outstanding Shares: 136,732,000
  • Beta: 1.72
Additional Links:
Companies Related to Nektar Therapeutics:

Analyst Ratings

Consensus Ratings for Nektar Therapeutics (NASDAQ:NKTR) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.75 (8.76% upside)

Analysts' Ratings History for Nektar Therapeutics (NASDAQ:NKTR)
DateFirmActionRatingPrice TargetDetails
8/5/2016Piper Jaffray Cos.Reiterated RatingOverweight$17.00 -> $21.00View Rating Details
8/5/2016Brean CapitalReiterated RatingBuy$18.00View Rating Details
2/19/2016Roth CapitalReiterated RatingBuyView Rating Details
2/12/2016William BlairReiterated RatingBuyView Rating Details
1/27/2016Janney Montgomery ScottInitiated CoverageBuy$21.00View Rating Details
3/18/2015JPMorgan Chase & Co.Lower Price TargetOverweight$19.00 -> $17.00View Rating Details
3/18/2015Jefferies GroupLower Price TargetBuy$17.00 -> $14.00View Rating Details
9/17/2014Bank of America Corp.Reiterated RatingUnderperform$10.00 -> $11.00View Rating Details
(Data available from 8/23/2014 forward)


Earnings History for Nektar Therapeutics (NASDAQ:NKTR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2016Q216($0.33)($0.36)$34.17 million$32.77 millionViewListenView Earnings Details
5/3/2016Q1($0.23)($0.14)$43.78 million$58.88 millionViewN/AView Earnings Details
3/1/2016Q4($0.42)($0.40)$28.82 million$39.40 millionViewListenView Earnings Details
11/5/2015Q315($0.24)($0.06)$44.30 million$60.00 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.40)$21.49 million$22.66 millionViewN/AView Earnings Details
4/30/2015Q115($0.40)$0.25$20.20 million$108.80 millionViewN/AView Earnings Details
2/24/2015Q414($0.36)($0.35)$12.30 million$19.55 millionViewN/AView Earnings Details
11/6/2014Q314$0.39$0.53$123.20 million$132.90 millionViewN/AView Earnings Details
7/31/2014Q214($0.37)($0.26)$19.76 million$28.50 millionViewListenView Earnings Details
5/7/2014Q114($0.19)($0.37)$38.68 million$19.80 millionViewListenView Earnings Details
2/26/2014Q413($0.17)($0.41)$49.26 million$31.15 millionViewN/AView Earnings Details
11/7/2013Q313($0.22)($0.14)$54.34 million$60.91 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.44)($0.37)$26.22 million$33.86 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.42)($0.48)$26.30 million$23.00 millionViewN/AView Earnings Details
11/9/2012Q312($0.39)($0.38)$21.02 million$18.41 millionViewN/AView Earnings Details
8/9/2012($0.33)($0.30)ViewN/AView Earnings Details
5/2/2012($0.33)($0.36)ViewN/AView Earnings Details
2/29/2012($0.47)($0.33)ViewN/AView Earnings Details
11/2/2011($0.37)($0.21)ViewN/AView Earnings Details
8/4/2011($0.31)($0.32)ViewN/AView Earnings Details
4/27/2011($0.27)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Nektar Therapeutics (NASDAQ:NKTR)
Current Year EPS Consensus Estimate: $-1.11 EPS
Next Year EPS Consensus Estimate: $-0.86 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.36)($0.14)($0.23)
Q2 20162($0.35)($0.31)($0.33)
Q3 20163($0.34)($0.27)($0.30)
Q4 20163($0.31)($0.17)($0.23)
Q1 20171($0.21)($0.21)($0.21)
Q2 20171($0.21)($0.21)($0.21)
Q3 20171($0.21)($0.21)($0.21)
Q4 20171($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)


Dividend History for Nektar Therapeutics (NASDAQ:NKTR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Nektar Therapeutics (NASDAQ:NKTR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2016Gil M. LabrucherieCFOSell3,305$17.56$58,035.80View SEC Filing  
8/16/2016Howard W. RobinCEOSell11,817$17.56$207,506.52View SEC Filing  
8/16/2016John NicholsonCOOSell3,317$17.56$58,246.52View SEC Filing  
8/16/2016Stephen K. DobersteinSVPSell1,336$17.56$23,460.16View SEC Filing  
8/1/2016Robert ChessDirectorSell5,000$17.26$86,300.00View SEC Filing  
7/11/2016Jillian B ThomsenCAOSell100,000$15.09$1,509,000.00View SEC Filing  
7/1/2016Robert ChessDirectorSell5,000$14.10$70,500.00View SEC Filing  
5/17/2016Gil M LabrucherieSVPSell836$13.58$11,352.88View SEC Filing  
5/17/2016Howard W RobinCEOSell2,170$13.58$29,468.60View SEC Filing  
5/17/2016Jillian B ThomsenCAOSell724$13.58$9,831.92View SEC Filing  
5/17/2016John NicholsonCFOSell856$13.58$11,624.48View SEC Filing  
4/25/2016Lutz LingnauDirectorSell15,000$16.27$244,050.00View SEC Filing  
2/17/2016Howard W. RobinCEOSell2,147$11.92$25,592.24View SEC Filing  
2/17/2016Jillian B. ThomsenCAOSell716$11.92$8,534.72View SEC Filing  
2/17/2016Maninder HoraSVPSell963$11.92$11,478.96View SEC Filing  
2/10/2016Gil M. LabrucherieSVPSell11,666$11.49$134,042.34View SEC Filing  
2/10/2016Howard W. RobinCEOSell66,666$11.49$765,992.34View SEC Filing  
2/10/2016Jillian B. ThomsenCAOSell15,000$11.49$172,350.00View SEC Filing  
1/20/2016Lutz LingnauDirectorSell15,000$14.51$217,650.00View SEC Filing  
1/19/2016Gil M. LabrucherieSVPSell11,667$14.12$164,738.04View SEC Filing  
1/19/2016Howard W. RobinCEOSell66,667$14.12$941,338.04View SEC Filing  
1/19/2016Jillian B. ThomsenCAOSell15,000$14.12$211,800.00View SEC Filing  
12/4/2015Christopher A. KueblerDirectorSell15,000$15.82$237,300.00View SEC Filing  
12/3/2015Gil M. LabrucherieSVPSell45,001$15.87$714,165.87View SEC Filing  
12/3/2015Howard W. RobinCEOSell125,001$15.87$1,983,765.87View SEC Filing  
12/3/2015Jillian B. ThomsenCAOSell15,000$15.87$238,050.00View SEC Filing  
11/20/2015Susan WangDirectorSell85,000$15.02$1,276,700.00View SEC Filing  
11/11/2015Gil M. LabrucherieSVPSell45,000$13.52$608,400.00View SEC Filing  
11/11/2015Howard W. RobinCEOSell125,000$13.52$1,690,000.00View SEC Filing  
11/11/2015Jillian B. ThomsenCAOSell15,000$13.52$202,800.00View SEC Filing  
10/28/2015Lutz LingnauDirectorSell12,500$12.00$150,000.00View SEC Filing  
10/6/2015Gil M. LabrucherieSVPSell45,000$10.99$494,550.00View SEC Filing  
10/6/2015Howard W. RobinCEOSell125,000$10.99$1,373,750.00View SEC Filing  
10/6/2015Jillian B. ThomsenCAOSell15,000$10.99$164,850.00View SEC Filing  
9/23/2015Gil M. LabrucherieSVPSell44,999$13.04$586,786.96View SEC Filing  
9/23/2015Howard W. RobinCEOSell124,999$13.04$1,629,986.96View SEC Filing  
9/23/2015Jillian B. ThomsenCAOSell10,000$13.04$130,400.00View SEC Filing  
8/13/2015Gil M LabrucherieSVPSell33,333$10.89$362,996.37View SEC Filing  
8/13/2015Howard W RobinCEOSell58,333$10.89$635,246.37View SEC Filing  
7/14/2015Gil M LabrucherieSVPSell33,334$11.78$392,674.52View SEC Filing  
7/14/2015Howard W RobinCEOSell58,334$11.78$687,174.52View SEC Filing  
6/29/2015Susan WangDirectorSell30,000$12.70$381,000.00View SEC Filing  
6/19/2015Robert ChessDirectorSell15,000$11.81$177,150.00View SEC Filing  
6/15/2015Lutz LingnauDirectorSell25,000$11.15$278,750.00View SEC Filing  
12/29/2014Robert ChessDirectorSell29,500$15.34$452,530.00View SEC Filing  
12/22/2014Jillian B ThomsenCAOSell5,000$15.56$77,800.00View SEC Filing  
12/1/2014Gil M LabrucherieSVPSell120,000$17.02$2,042,400.00View SEC Filing  
12/1/2014Howard W RobinCEOSell350,000$17.01$5,953,500.00View SEC Filing  
11/25/2014Howard W RobinCEOSell600,000$15.25$9,150,000.00View SEC Filing  
11/24/2014Gil M LabrucherieSVPSell10,500$15.04$157,920.00View SEC Filing  
11/24/2014Howard W RobinCEOSell132,800$15.02$1,994,656.00View SEC Filing  
11/24/2014Lutz LingnauDirectorSell15,000$15.02$225,300.00View SEC Filing  
11/3/2014Gil M LabrucherieSVPSell9,900$13.78$136,422.00View SEC Filing  
8/5/2013Roy WhitfieldDirectorSell12,500$12.41$155,125.00View SEC Filing  
9/14/2012Dennis L WingerDirectorBuy5,000$9.18$45,900.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Nektar Therapeutics (NASDAQ:NKTR)
DateHeadline logoNektar Therapeutics (NASDAQ:NKTR) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:NKTR) - August 23 at 10:52 AM logoETF’s with exposure to Nektar Therapeutics : August 22, 2016 (NASDAQ:NKTR) - August 22 at 6:25 PM
News IconMu-Opioid Analgesic in Phase III (NASDAQ:NKTR) - August 19 at 9:32 AM logoNektar Therapeutics (NASDAQ:NKTR) Trading Up - Insiders Are Selling - Finance Daily (NASDAQ:NKTR) - August 17 at 6:43 PM logoWill Nektar Therapeutics (NASDAQ:NKTR) Hit $20 Price Target? - Investor Newswire (NASDAQ:NKTR) - August 17 at 9:33 AM logoIncremental Progress At Nektar Therapeutics - Seeking Alpha (NASDAQ:NKTR) - August 17 at 9:33 AM logoIncremental Progress At Nektar Therapeutics (NASDAQ:NKTR) - August 16 at 6:36 PM logoWill Nektar Therapeutics (NASDAQ:NKTR) Surprise This Quarter? - Investor Newswire (NASDAQ:NKTR) - August 14 at 10:56 AM logoNEKTAR THERAPEUTICS Financials (NASDAQ:NKTR) - August 12 at 6:35 PM logoETF’s with exposure to Nektar Therapeutics : August 11, 2016 (NASDAQ:NKTR) - August 11 at 6:55 PM logoGlobal Dendrimers and Polymer Drug Conjugates Market 2016 with 10 Year Forecasts - Research and Markets (NASDAQ:NKTR) - August 9 at 9:37 AM logoNektar Therapeutics :NKTR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016 (NASDAQ:NKTR) - August 8 at 6:39 PM logoNektar Therapeutics (NKTR) Shares are Up 1.68% - Trade Calls (NASDAQ:NKTR) - August 8 at 11:10 AM logoNektar Therapeutics’ Sweet Pipeline (NASDAQ:NKTR) - August 7 at 10:37 AM logoNektar Therapeutics (NASDAQ:NKTR) Yearly Sales Target At $448.688 - Investor Newswire (NASDAQ:NKTR) - August 5 at 6:40 PM logoCurrent Analysts Rating Update: Astrazeneca PLC (NYSE:AZN) , Nektar Therapeutics (NASDAQ:NKTR) - Street Updates (NASDAQ:NKTR) - August 5 at 6:40 PM logo[$$] Nektar Therapeutics' Sweet Pipeline (NASDAQ:NKTR) - August 5 at 6:40 PM logoNektar Therapeutics (NKTR): String of Catalysts Spurs PT Increase - Piper Jaffray (NASDAQ:NKTR) - August 4 at 6:50 PM logoDon't Roll the Dice on Central Bank News (NASDAQ:NKTR) - August 4 at 6:50 PM logoNEKTAR THERAPEUTICS Files SEC form 10-Q, Quarterly Report (NASDAQ:NKTR) - August 4 at 6:50 PM logoEdited Transcript of NKTR earnings conference call or presentation 3-Aug-16 9:00pm GMT (NASDAQ:NKTR) - August 4 at 9:37 AM logoEARNINGS SUMMARY: Details of Nektar Therapeutics Q2 Earnings Report (NASDAQ:NKTR) - August 3 at 6:47 PM logoNektar Therapeutics Reports Financial Results for the Second Quarter of 2016 (NASDAQ:NKTR) - August 3 at 6:47 PM logoNektar reports 2Q loss (NASDAQ:NKTR) - August 3 at 6:47 PM logoNEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib (NASDAQ:NKTR) - August 3 at 6:47 PM logoNektar Therapeutics Earnings Call scheduled for 5:00 pm ET today (NASDAQ:NKTR) - August 3 at 6:47 PM logoBiotech Stocks Technical Report -- Arena Pharma, BIND Therapeutics, Nektar Therapeutics, and Regeneron Pharma (NASDAQ:NKTR) - August 3 at 9:46 AM logoQ2 2016 Nektar Therapeutics Earnings Release - After Market Close (NASDAQ:NKTR) - August 3 at 9:46 AM
News IconHC Stocks Momentum: HealthSouth Corp (NYSE:HLS) Nektar Therapeutics (NASDAQ:NKTR) - share market updates (press release) (NASDAQ:NKTR) - August 1 at 6:11 PM logoNektar Therapeutics (NKTR) Worth a Look: Stock Gains 6.1% - Nasdaq (NASDAQ:NKTR) - July 31 at 10:31 AM logoNektar Therapeutics (NKTR) Jumps 6.13% on July 28 (NASDAQ:NKTR) - July 29 at 6:37 PM logoCommit To Buy Nektar Therapeutics At $13, Earn 11.1% Annualized Using Options (NASDAQ:NKTR) - July 29 at 6:37 PM logoNektar Therapeutics (NKTR) Worth a Look: Stock Gains 6.1% (NASDAQ:NKTR) - July 29 at 8:45 AM logoNektar Therapeutics (NKTR) Jumps 6.13% on July 28 - (NASDAQ:NKTR) - July 28 at 6:42 PM logoNoticeable Analyst's ideas: Edwards Lifesciences Corporation (NYSE:EW) , Nektar Therapeutics (NASDAQ:NKTR) - Street Updates (NASDAQ:NKTR) - July 28 at 9:40 AM logoNektar to Announce Financial Results for the Second Quarter 2016 on Wednesday, August 3, 2016, After Close of U.S.-Based Financial Markets (NASDAQ:NKTR) - July 27 at 5:28 PM logoSummary of Analyst's Study: Dr. Reddy's Laboratories Ltd (NYSE ... - Street Updates (NASDAQ:NKTR) - July 27 at 9:28 AM logoNektar Therapeutics (NKTR) Shares are Down -1.62% - Trade Calls (NASDAQ:NKTR) - July 26 at 6:46 PM logoAnalysts Review of Stocks: Endo International (NASDAQ:ENDP) , Nektar Therapeutics (NASDAQ:NKTR) - Street Updates (NASDAQ:NKTR) - July 23 at 6:01 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Nektar Therapeutics (NASDAQ:NKTR) - TGP (NASDAQ:NKTR) - July 21 at 6:45 PM logoAegerion to Withdraw Juxtapid from EU, Reduces Workforce (NASDAQ:NKTR) - July 21 at 9:21 AM
News IconNektar Therapeutics (NASDAQ:NKTR): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:NKTR) - July 20 at 9:23 AM
News IconShares Positive Over the Past Month: Nektar Therapeutics (NASDAQ:NKTR) - TGP (NASDAQ:NKTR) - July 20 at 9:23 AM logoBristol-Myers' Opdivo Label Expansion Under U.S., EU Review (NASDAQ:NKTR) - July 19 at 6:33 PM logoForm 4 NEKTAR THERAPEUTICS For: Jul 14 Filed by: Thomsen Jillian B. (NASDAQ:NKTR) - July 19 at 6:33 PM
News IconShare Performance Summary for: Nektar Therapeutics (NASDAQ:NKTR) - Press Telegraph (NASDAQ:NKTR) - July 19 at 9:35 AM
News IconTrading Performance and Target Watch for Nektar Therapeutics (NASDAQ:NKTR) - Press Telegraph (NASDAQ:NKTR) - July 18 at 6:35 PM logoIs $20 Price Target Attainable For Nektar Therapeutics (NASDAQ:NKTR)? - Investor Newswire (NASDAQ:NKTR) - July 18 at 6:35 PM logoShares of Nektar Therapeutics (NKTR) Rally 3.55% - Trade Calls (NASDAQ:NKTR) - July 18 at 6:35 PM
News IconHot Biotech Stocks Recap: Nektar Therapeutics (NASDAQ:NKTR), Halozyme Therapeutics, Inc. (NASDAQ:HALO) - The Voice Registrar (NASDAQ:NKTR) - July 15 at 11:17 AM


Nektar Therapeutics (NASDAQ:NKTR) Chart for Tuesday, August, 23, 2016

Last Updated on 8/23/2016 by Staff